Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLTP | P55058 | 10/20 | 0.63 |
| ▸ | RRM1 | P23921 | 2/20 | 0.58 |
| ▸ | RRM2B | Q7LG56 | 2/20 | 0.58 |
| ▸ | TOP1 | P11387 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SNCA | P37840 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10002075 | 0.85 | PLTP (0.86) | PLTPRRM1RRM2BTOP1MAPT | |
| Coh-29 SCHEMBL31436912 | 0.81 | PLTP (0.61) | PLTPRRM1RRM2BTOP1MAPT | |
| Coh-29 SCHEMBL29424344 | 0.81 | PLTP (0.61) | PLTPRRM1RRM2BTOP1MAPT | |
| Coh-29 SCHEMBL10036527 | 0.81 | PLTP (0.61) | PLTPRRM1RRM2BTOP1MAPT | |
| SCHEMBL1304878 | 0.78 | PLTP (1.00) | PLTPRRM1RRM2BTOP1 | |
| SCHEMBL12940263 | 0.76 | PLTP (0.59) | PLTPRRM1RRM2BTOP1MAPT | |
| SCHEMBL10036571 | 0.74 | RRM1 (1.00) | PLTPRRM1RRM2BTOP1MAPT | |
| SCHEMBL19638141 | 0.73 | ADORA3 (0.56) | — | |
| SCHEMBL1304117 | 0.72 | PLTP (1.00) | PLTPRRM1RRM2BTOP1 | |
| SCHEMBL1302909 | 0.72 | PLTP (1.00) | PLTPTOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2809662-B1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | HOPE CITY (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180155303-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2018-06-07 | — | — | US | disclosed |
| US-20180155303-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2018-06-07 | — | — | US | disclosed |
| US-9796692-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796692-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170137392-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2017-05-18 | — | — | US | disclosed |
| US-20170137392-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2017-05-18 | — | — | US | disclosed |
| US-9598385-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598385-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160122308-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2016-05-05 | — | — | US | disclosed |
| US-20120253048-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2012-10-04 | — | — | US | disclosed |
| US-20120253048-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2012-10-04 | — | — | US | disclosed |
| US-8163783-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163783-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110245304-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2011-10-06 | — | — | US | disclosed |
| US-20110245304-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2011-10-06 | — | — | US | disclosed |
| US-7956076-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2011-06-07 | — | — | US | disclosed |
| US-7956076-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2011-06-07 | — | — | US | disclosed |
| US-20090258915-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2009-10-15 | — | — | US | disclosed |
| US-20090258915-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122308-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885RRM1 3/4885RRM2B 2/4885 |
| US-20090258915-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4112/4885RRM1 3/4885RRM2B 2/4885 |
| US-20180155303-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885RRM1 3/4885RRM2B 2/4885 |
| US-20170137392-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885RRM1 3/4885RRM2B 2/4885 |
| US-20120253048-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885RRM1 3/4885RRM2B 2/4885 |
| US-20110245304-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4112/4885RRM1 3/4885RRM2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.